Journal of Internal Medicine 2003; 253: 671-675 Author index Aagaard, N.K., Andersen, H., Vilstrup, H., Clausen, T., Jakobsen, Bos, G. see Becker, A. J. & Dorup, I. Decreased muscle strength and contents of Mg 36ttiger, B.W. & Spodhr, F. The risk of thrombolysis in association and Na,K-pumps in chronic alcoholics occur independently with cardiopulmonary resuscitation: no reason to withhold of liver cirrhosis, 359 this causal and effective therapy, 99 Agren, L. see Lantz, H. Bouter, L.M. see Becker, A. Ahlbom, A. see Farahmand, B.Y. Braithwaite, S. see Stanciu, I.N. Ahlbom, A. see Hammar, N. Brismar, K. see Degerblad, M. Alayash, A.I. see Yeh, L.-H. Buirma, R.J.A. see De Sauvage Nolting, P.R.W Alfredsson, L. see Hammar, N. Andersen, H. see Aagaard, N.K. Cabello, A. see Garcia-Velasco, A. Andersson, T. see Hammar, N. Cadet, E., Capron, D., Perez, A.S., Crépin, S.N., Arlot, S., Ducroix, Aoki, S. see Nishio, K. ].-P., Dautréaux, M., Fardellone, P., Leflon, P.. Merryweather- Arenas, J. see Garcia-Velasco, A. Clarke, A.T., Livesey, K.J., Pointon, J.J.. Rose, P.. Harcourt, J., Arlot, S. see Cadet, E. Armstrong, V.W. see Schettler, V. Emery, J., Sueur, J.M., Feyt, R.. Robson, K.J.H. & Rochette, J. A targeted approach significantly increases the identification Arner, P. see Uddeén, J. rate of patients with undiagnosed haemochromatosis, 217 Aronson, D. see Farahmand, B.Y. Campos,Y . see Garcia-Velasco, A. Asplund, K. see Rodu, B. Candelli, M., Nista, E.C., Pignataro, G., Zannoni, G., De Pascalis, Attvall, S. see Bonnier, M. B., Gasbarrini, G. & Gasbarrini, A. Steatohepatitis during Axelsson, C. see Svensson, L. methylprednisolone therapy for ulcerative colitis exacerba- tion, 391 Bakken, A. see Retterstol, L. Capron, D. see Cadet, E. Baljé-Volkers, C.P. see Verhave, J.C. Carpten, J.D. see Chen, J.D. Bankl, H.C. see Kurkciyan, I. Celsing, F. Should pseudopolycythaemia be treated?, 399 Barkeling, B. see Uddeén, J. Ceriani, L. see Malerba, M. 3aughman, R.P. & Lynch, J.P. Difficult treatment issues in Chandrasekharappa, S.C. & Teh, B.T. Functional studies of the sarcoidosis, 41 MENT gene, 606 Becker, A., Kostense, P.J., Bos, G., Heine, R.J., Dekker, J.M., Chang, T.M.S. Future generations of red blood cell substitutes, Nijpels, G., Bouter, L.M. & Stehouwer, C.D.A. Hyperhomo 5 —) cysteinaemia is associated with coronary events in type 2 ‘harfeddine, H. see Marquez, M.P. diabetes, 293 ‘hen, J.D., Morrison, C., Zhang, C., Kahnoski, K., Carpten, J.D. & Beckers, A., Betea, D., Valdes Socin, H. & Stevenaert, A. The leh, B.T. Hyperparathyroidism-jaw tumour syndrome, 634 treatment of sporadic versus MEN 1-related pituitary adenomas, 599 ‘how, K.-M. see Szeto, C.-C. Beevers, D.G. see Felmeden, D.C. ‘ioffi, M. see Mossetti, G. Ben-Ari, Z., Mor, E. & Tur-Kaspa, R. Experience with ‘lausen, T. see \agaard, N.K. ‘ohen, M.S. & Moley, J.F. Surgical treatment of medullary thyroid lamivudine therapy for hepatitis B virus infection before carcinoma, 616 and after liver transplantation, and review of the ‘ole, P. see Rodu, B. literature, 544 ‘ossburn, M. see Biswas, M. Berg, K. see Os, I. Berg, K. see Retterstol, L raddock, C. see Ma, Y.T. ‘répin, S.N. see Cadet, E. Berggren Séderlund, M., Fex, G. & Nilsson-Ehle, P. Decreasing ‘ullinan, P. see du Bois, R.M. serum concentrations of all-trans, 13-cis retinoic acids and retinol during fasting and caloric restriction, 375 Berglund, G. see Engstrém, G. Dautréaux, M. see Cadet, E. Berglund, G. see Nilsson, P. De Jong, P.E. see Verhave, J.C Berglund, G. see Nordin Fredrikson, G. De Paola, A.A.V. see Veloso, H.H. 3etea, D. see Beckers, A. De Pascalis, B. see Candelli, M. Bilo, H.J.G. see De Visser, C.L. De Pergola, G. see Resta, O. Birkeland, K. see Os, | De Sauvage Nolting, P.R.W., Defesche, J.C., Buirma, R.J.A., Biswas, M., Prakash, P.K., Cossburn, M., Myers, K. & Hanna, F. Hutten, B.A., Lansberg, P.J. & Kastelein, J.J.P. Prevalence and Life-threatening thrombotic complications of relative poly significance of cardiovascular risk factors in a large cohort of cythaemia, 481 patients with familial hypercholesterolaemia, 161 3itterman, H. see Dori, G. Visser, C.L., Bilo, H.J.G.. Thomsen, T.F.. Groenier, K.H. & 3j6rkholm, B., Falk, P., Engstrand, L. & Nyrén, O. Helicobacter Meyboom-De Jong, B. Prediction of coronary heart disease: a pylori: resurrection of the cancer link, 102 comparison between the Copenhagen risk score and the Bjorntorp, P. see Uddeén, J. Framingham risk score applied to a Dutch population, 553 Blann, A.D. see Felmeden, D.C. De Zeeuw, D. see Verhave, J.C Blockmans, D. see Knockaert, D.C. Defesche, J.C. see De Sauvage Nolting, P.R.W. Bohn, M. see Retterstol, L. Degerblad, M., Brismar, K., Rahn, T. & Thorén, M. The du Bois, R.M., Goh, N., McGrath, D. & Cullinan, P. Is there a role hypothalamus-—pituitary function after pituitary stereotactic for microorganisms in the pathogenesis of sarcoidosis?, 4 radiosurgery: evaluation of growth hormone deficiency, 454 Bontfitto, P. see Resta, O. Dekker, J.M. see Becker, A Bonnier, M., Lonnroth, P., Gudbjérnsdottir, S., Attvall, S. & Denekamp, Y. see Dori, G. Jansson, P.-A. Validation ofa glucose—insulin—potassium Depalo, A. see Resta, O. infusion algorithm in hospitalized diabetic patients, 189 Dilek, K. see Usta, M. © 2003 Blackwell Publishing Ltd 672 AUTHOR INDEX Grassi, V. see Malerba, M. DDDDjooourhmirea.or nvttsioytyGcpvr.,e,e.i s ts sGDS1..,e: M t n.edss eetueHki .on a&gd Om.ess pe,nTe, oh mpo|Kya muoYnp.rcc,ska rocreFindaiy.itsaa hinlmc, Na .npW,|e t rufmuSoM.s uuilro&tsn i, pB liietm 5ta9eegr0nmi danong,c riannHed. Esnxteerroe spsl asia GGGGuruuluoedlseirbitnrjlaiaiéfie-r,s!Vn s asoldnMeo,.Ks t.,tH .iSse .reA ,.J .seMUe.s S st$e.e a D,see s ce Le MoVGw iBabsorsenecenriri,a, e- rVC e.C1l aMs co, A hocardiography for detecting restenosis alter suc sstul percutaneous transluminal coronary angi HHaigiegr,g ,E .S. see see RMoellacnhdasrsto n, D O performance, 253 Halinen, M. see Hyttinen, | SCE \agaard N.K Hallmans, G. see Rolandsson, O see Cadet, I Hallmarker, U. see Farahmand, B.Y Hallqvist. J. see Hammar, N. Ebenbichler, C.F. see Kaser, 5 Hamada, 1 Ekblom, B. see Farahmand, B.‘ Hammar, N Alfredsson, L., Reuterwall, C Ekblom, 0. see Farahmand, B. Nilsson allqvist, J.. Knutsson, A. & \hibom, A Eklund, A. Aetiology, pathogene soiled and filtered coffee with incidence of first Ellegaard, J. see Hvas, A.-M ction: the SHEEP and the VHEEP Emanuele, M.A. see Stanciu, I.N. Emery, J. see Cadet, I Hanna, F. EEnnggssttrréamn,d , G.L,. Hseee dblBajdé,r khBo.,l m,Ni lsBs on P.>, Wollmer, P.. Berglund, G. & HHaanrscsoounr,t , |J . see Cadet, E. cJaanrzdoino,v asLc.u lLaurn g difsuenacset:i on,a lonnsguilitnu dirneasli stcaonhcoer t ansdt udiyn,c id5e7n4c e of HHaarsdhairmsootno,, MTh.. sseeee KTuhrroakianswdao,t tirK, 1.5. ) Erikssen, J. see Retterstol, | Hassager, C. see Riis Hansen, | Eriksson, K.-F. see Nilsson, P Hayakawa, T. see Okamura, 11 Ersoy, A. see Usta M. Hedblad, B. see Engstr6m, G Hedblad. B. see Nilsson. P Fagerberg, B. see Schmidt, C. Hedblad. B. see Nordin Fredrikson, G Fagrell, B. see Holm, G. Heimbiirger, 0. see Lowbeer, C Falk, P. see Bjorkholm, B Heine, R.J. see Becker, A Farahmand, B.Y.. Ahlbom, A., Ekblom, O.. Ekblom, B., Hallman lerlitz, J. see Svensson, L. ker. U.. Aronson, D. & Persson Brobert, G. Mortality amongst Hidden-Lucet, F. see Marquez, M.1 participants in Vasaloppet: a classical long-distance ski race Hillege, H.L. see Verhave, J.C. Fardelinl onSew,e dePn. , see 27C6a det, E. HHooilemg,g enG,. & AF.a gsreeel l,O s, B. I. The Journal of Inter nal Medicine launches an Felmeden, D.C.. Spencer, C.G.C., Blann, A.D. Beevers, D.G. & Lip. electronic submission and peer-review system, 49 3 G.Y.H. Physical activity in relation to indices of endothelial Holzl, B. see Kaser, S. function and angiogenesis factors in hypertension: a Hovind, P. see Jacobsen, Pr substudy of the Anglo-Scandinavian ( ardiac Outcomes Trial Hulthe, J. see Schmidt, C. FFFFeeeixyort.rg, eu n(sGtA.oRi S.nn C,isOe, seTe e)E ,C.B . Ce asredsge8ee ge1t r ,Le LonuwI ce r,eS zéidoKe.tCrt.il ,u ndS,. M HHHvuuatmstp.eh ntar,rim eeoAas.nBt-,.gMm A.e ., n tSi. nsJEedu.eu i hlv,asi Dsedee u S.al,SSli tamseiN utpevewhxadieo gtn,he se ,ff Ee.eN lcoJte&l .v tWaio.tEnn el gdl, e hgeapPaall.radtRs,h.m -War. e Jl.m aVetiettdha ymlqimunaa llioBtn-yi 12co f alciifde : FFFoiorssohcnmhiai,nn o,C . BS.sa ere bseae LruocD,ro erzii.M o.Pt.tG .i , seeS . Resta, O. Hvttianm eynro,pa enrdLio.c,m airKzdaeiidtp iisap ilnainec nea-bsoSs-eocpcopinaatntrieoonln,l edwO i.t sht& u dCHyr,ao lhinn1'e4sn6 , diMs.e asRee, cur3r8e6n t Frank, R. see Marquez, M.P. Frick, M. see Ryman, J to, Y. see Kurokawa, kK. Frvkman. V. see Ryman, J. toh, S. see Nishio, K. Gambacirynofc.ll aomoGmx. aytg&oe rnyPa esreaa zgeelinlntahs,i: b itMeo.vrAas.,l ua6tA4id3ovn e rsoef sreelneaclt iveef feacntds onfo nasnetli-e ctive acobsBneienrpt,hh roPw.p,ea itgRhhoyst?s ,i—n g ,a3 4r3Pi. s,k Tafarcntoorw , forL .,p rHoogvriensds,i onP . I&n Pdairabveitnigc, H.-H. akate, S. see Stanciu, I.N. Gander, R. see Kaser, S GarciCaa-bVeelllaos,c o,A .. AC.,a mGpoomse,z -EYs.c a&l onAirlelnaa,s, C.J,. IGnuteesrtrian alV alpesse, udJo. M.. Jaankeorb,s enM,. sJe.e seRe olAaangdasasrodn,, NO..K . ombisttorcuhcotnidorni ala nd DNuAr-irnealrya terde tednitsieoans:e , ca3r8d|i n al features of a aaénnnszssosonon,n, , L.PB ..-,s Aee. HaEnsnesegs sotBnro,né nmi,Le. r,&G . SMt alhammar, N.-O. Health economics Gasbarrini, A. see Candelli, M. in the Hypertension Optimal Treatment (HOT) study: costs Gasbarrini, G. see Candelli, M. and cost-effectiveness of intensive blood pressure lowering Gaur, L.K. see Rolandsson, O. and low-dose aspirin in patients with hypertension, 472 Genschel, J. see Tietge, U.J.P. Juul, S. see Hvas, A.-M. Giliberti, T. see Resta, O. Giordano, F. see Mossetti, G. Kadowaki, T. see Okamura, T. Goh, N. see du Bois, R.M. GGoomredzo-nE,s caDl. onseiel lSat,a ncCi.u ,s ee I.GN.a rcia-Velasco, A KKaahinpoisakiin,e n-KS. epsepea nCehne,n , O.J .Ds.e e Hyttinen, L 2003 Blackwell Publishing Ltd Journal of Internal Medicine 253: 671-675 AUTHOR INDEX 673 Karlsson, E. see Lindenberger, M. McGrath, D. see du Bois, R:M Kaser, S. Sandhofer, A., Hélzl, B., Gande! R., Ebenbichler, C.I Malerba, M., Radaeli, A., Ceriani, | lantucci, C. & Grassi, V. Paulweber, B. & Patsch, J.R. Phospholipid and cholestery \irway hyper ‘sponsiveness in a large group of subjects with ester transfer are increased in lipoprotein lipase deficiency ¥,;-antitrypsin deficiency: a cross-sectional controlled stud) 208 51 Kastelein, lak. see De Sauvage Nolting, P.R.W Malinow, M.R. sec Retter stol, L. Katagiri, T. see Nishio, K Marquez, M.1 Sobrino A.N Rome Kawai, K. sec Kurokawa, K Hid( ]1d en-Lu s<ihara Y., Hamada lr.& Otsuki, M. Facial flushing and localiz isoprolereno! eceh a ' Castleman's« lisease an extension of the POEMS syndrome nonspecilk repolarization ibnorma phenotype reply 249 yncope, 244 Kita, \ see Okamura, |] Matsuo, Y. see Nakanishi, N Kjellberg, M. see Lindenberger M. Melchart, D., Thormaehlen, J., Hager, ‘ Kjellstr6m, B.T. Blood substitutes: where do we stand today 195 Weidenhammer, W. Acupuncture Kleinoeder, T. see Schettler, \ sumatriptan for early treatment Knockaert, 1.4 Vanderschueren, S. & Blockmans, D. Fever of randomized controlled trial, unknown origin in adults: tO years on, 263 Meron, G Knutsson, A. SEC Hammar, N Merryw ather \ Konno, N SEC Nishio, K Messner, T. & Lundberg, \ | Kostense, P J. see Becker, A northern Sweden MONIC Koster, M. sec Rosengren, a; Messner, T., Lun V.& W Ktihn, W. see Schettler, \ and incidence of acute myocardial int Kurkciyan, I., Meron, G., Sterz, F., Miillner, M., Tobler, K., Meurling, | see Uddeén, J Domanovits, H., Schreiber, W., Bankl, H.C. & Laggner, A.N Meyboom-D« Jong, B. s Major bleeding complications after cardiopulmonary resus Moley. J.F. see Cohen, M citation: impact of thrombolytic treatment, 128 Moller, D.R. lreatment of sarcoidosis Kurokawa, K., Kawai, K. Hashimoto, M.., Ito, Y. & Takahashi, M of view, 31 Cell signalling and gene expression mediated by RET tyrosine Mor, E. see Ben-Ari, 7 kinase, 627 Morrison, C. see Chen, J.D Kurtovic, J. & Riordan, $.M. Paracetamol-induced hepatotoxicity Mossetti, G., Vuotto, P.. Rendina, D., Numis, F.G., Viceconti, R at recommended dosage, 240 Giordano, F., Ciofli, M., Scopacasa, F. & Nunziata, V. \ssociation between vitamin D receptor gene polymorphisms Laggner, A.N. see Kurkciyan, I. and tubular citrate handling in calcium nephrolithiasis, 194 Lansberg, P.J. see De Sauvage Nolting, P.R.W Mukae, S. see Nishio, K Lantz, H., Peltonen, M., Agren, L. & Torgerson, J.S. Intermittent Miiller, G.A. see Schettler, V. versus on-demand use of a very low calorie diet: a Miiller-Quernheim, J. see Ziegenhagen, M.W randomized 2-year clinical trial, 463 Miillner, M. see Kurkciyan, I. Larsen, A. see Os, L. Myers, K. see Biswas, M. Larsson, R. see Nygren, r, Leflon, P. see Cadet, | Nakanishi, N., Yoshida, H., Okamoto, M. Matsuo, Y . Suzuki, K. ¢ Lernmark, A. see Rolandsson, O. latara, K. \ssociation of alcohol consumption with Leung, C.-B. see Szeto, C.-C. white blood cell count a study of Japanese male office Li, P.K.-T. see Szeto, C.-C. workers, 367 Liao, J. see Melchart, D. Nasic, S. see Rodu, |5 Linde, K. see Melchart, D. Nexo, E. SC¢ Hvas, A.-M Lindenberger, M., Kjellberg, M., Karlsson, E. & Wranne, B. Nijpels, G. see Becker, A Pericardiocentesis guided by 2-D echocardiography: the Nilsson, J. see Nordin Fredrikson, G method of choice for treatment of pericardial effusion, +1] Nilsson, J.- \. see Nilsson, P Lindholm, B. see Lowbeer, C. Nilsson, M. see Rolandsson, O. Lip, G.Y.H. see Felmeden, D.C Nilsson, P., Ni sson, J.-A., Hedblad, B., Eriksson, K.-1 & Berglund Liu M.A. DNA vaccines: a review, H()2 G. Hyperinsulinaemia as long-term predictor of death and Livesey, KF. see Cadet, E. ischaemic heart disease in nondiabetic men: The Malm6é Lonnroth, P. See Bonnier, M. Preventive Project, 136 Lowbeer, C., Stenvinkel, P., Pecoits-Filho, R., Heimbiirger, O.., Nilsson, P. see Engstr6m, G Lindholm, B., Gustafsson, S.A. & Seeberger, A. Elevated Nilsson, 'T. see Hammar, N cardiac troponin T in predialysis patients is associated with Nilsson-Ehle, P. see Berggren Séderlund, M inflammation and predicts mortality, 153 Nishio, K., Mukae, S., Aoki, S., Itoh, S Konno, N., Ozawa, K. Lowe, K.C. & Ferguson, E. Benefit and risk perceptions in Satoh, R. & Katagiri, ‘] Congestive heart failure is associated transfusion medicine: blood and blood substitutes, 198 with the rate of bone loss $39 Lucreziotti, S., Foroni, C. & Fiorentini, C. Diagnostic and Nista, E.C. see Candelli, M prognostic role of cardiac troponins — reply, 389 Nordin Fredrikson, G., Hedblad, B., Berglund, G & Nilsson, J Lui, S.-F. see Szeto, C.-C. Plasma oxidized LDL: a predictor for acute myocardial Lundberg, V. see Messner, T. infarction?, 425 Lynch, '.P. see Baughman, R.P Nordlander, R see Svensson, | Numis, F.G. see Mossetti, G. Ma, Y.T., Weatherby, S.J., Rao, D.G., Winer, J.B., Craddock, C. & Nunziata, V. see Mossetti, G. Williams, A.C. Facial flushing and localized Castleman's Nygren, P. & Larsson, R. Overview of the clinical efficacy of disease: an extension of the POEMS syndrome phenotype, investigational anticancer drugs, 46 247 Nyren, O. see Bjérkholm, B © 2003 Blackwell Publishing Ltd Journal of Internal Medicine 253: 67 675 674 AUTHOR INDEX OOOekklaalmemrouitrcoah,,. MMT... . ssKeeeea dSoNcwahakekattnili,es rh,i T,., V.H Na yakawa, T., Kita, Y., Okayama, A RRuytmlaednwg,aer ,f aJr..Ei .nF rsiecesk ,o dRioMul.ma, ndFtsrhseyorknam,pa yn O,. p riVo. r & to Roesleenctgrviicsatl, caMr. diDouvreartsiioonn oolf & Ueshima, H. for the NIPPON DATA80 Research Group atrial fibrillation, 76 What cause of mortality can we predict by cholesterol screening in the Japanese general population?, 169 Sandhofer, A. see Kaser, S. Okayama, A. see Okamura, T. Sandset, P.M. see Os, I. Os, A. see Os, I Satoh, R. see Nishio, K. Os, I., Hoieggen, A., Larsen, A., Sandset, P.M., Djurovic, 5 Schettler, V., Kithn, W., Kleinoeder Armstrong, V.W 3erg, K., Os, A., Birkeland, K. & Westheim, A. Smoking and Oellerich. M., Miller, G.A. & Wieland, E. No acute impact ol relation to other risk factors in postmenopausal women with haemodialysis treatment on free radical scavenging enzyme coronary artery disease, with particular reference to whole gene expression in white blood cells, 201 blood viscosity and B-cell function, 232 Schmidt, C., Fagerberg, B., Wikstrand, J. & Hulthe, J. on behalf of Otsuki, M. see Kihara, Y The RIS Study Group. Multiple risk factor intervention Ozawa, K. see Nishio, K reduces cardiovascular risk in hypertensive patients with Ozdemir, B. see Usta, M echolucent plaques in the carotid artery, 430 Schmidt, H.H.-J. see Tietge, U.J.P. Schreiber, W. see Kurkciyan, | Pannacciulli, N. see Resta, O. Scopacasa, F. see Mossetti, G Parving, H.-H. see Jacobsen, P Seeberger, A. see Lowbeer, (¢ Patsch, J.R. see Kaser, S Shenenberger, D.W. see Riga. P.J. Paulweber, B. see Kaser, S Sigfusson, N. see Thrainsdottir, 1S. Paus, B. see Retterstol, L Sigvaldason, H. see Thrainsdottir, 1.5 Pecoits-Filho, R. see Lowbeer, C \.N. see Marquez, M.F. Peltonen, M. see Lantz, H. Spencer, C.G.C. see Felmeden, D.« Perazella, M.A. see Gambaro, G. Spohr, F. see Bottiger, B.W Perez, A.S. see Cadet,| Stalhammar, N.-O. see Jonsson, B Persson Brobert, G. see Farahmand, B.¥ Stanciu, I.N.. Pitale, S., Prinz, R.A., Jakate, $., Webb, G., Steiner Pignataro, G. seé Candelli, M D.. Braithwaite, S., Gordon, D. & Emanuele, M.A. Insulinoma Pitale, S. see Stanciu, LN. presenting with hyperandrogenism: a case report and a Pointon, J.J. se¢ Cadet, | literature review, 484 Prakash, P.K. see Biswas, M. Stegmayr, B. see Rodu, B Prinz, R.A. see Stanciu, I.N Stehouwer, C.D.A. see Becker, A. Steiner, D. see Stanciu, I.N Radaeli, A. sec Malerba, M Stenvinkel, P. see Lowbeer, C. Rahn, T. see Degerblad, M Stephens, J.W. & Humphries, S.E. The molecular genetics ol Rao, D.G. see Ma, Y.1 cardiovascular disease: clinical implications, 120 Rendina, D. see Mossetti, G Sterz, F. see Kurkciyan, | Resta. O., Foschino Barbaro, M.P., Bonfitto, P., Giliberti, ‘1 Stevenaert, A. see Beckers, A Depalo, A., Pannacciulli, N. & De Pergola, G. Low sleep Sueur, J.M. se¢ Cadet, | quality and daytime sleepiness in obese patients without Suzuki, K. see Nakanishi, N. obstructive sleep apnoea syndrome, 536 Svensson. L.. Axelsson, C., Nordlander, R. & Herlitz, J. Elevation of Retterstol, L.. Paus, B.. Bohn, M., Bakken, A., Erikssen, J biochemical markers for myocardial damage prior to hospital Malinow, M.R. & Berg, K. Plasma total homocysteine levels admission in patients with acute chest pain or other and prognosis in patients with previous pre mature myocal symptoms raising suspicion of acute coronary syndrome, 31 l dial infarction: a 10-year follow-up study, 284 Szeto, C.-C., Leung, C.-B., Wong, T.Y.-H., Chow, K.-M., Reuterwall Hammar, N Wang, A.Y.-M., Lui, S.-F. & Li, P.K.-T. Extrapolation ol , D.W. Di gnostic and pI reciprocal creatinine plot is not reliable in predicting the lac troponins onset of dialysis in patients with progressive renal Riis Hansen, P. & Hassager, C. Septal alcohol abla insufficiency, 335 syndrome revisited, 490 Riordan, S.M. see Kurtovic, J fakahashi, M. see Kurokawa Robson, K.J.H. see Cadet, | antucci, C. see Malerba, M Rochette, J. see Cadet, E. Rodu, B., Stegmayr, B., Nasic, S., Cole, P. & Asplund, K. Evolving arnow, L. see Jacobsen, P patterns of tobacco use in northern Sweden, 660 atara, K. see Nakanishi, N. Rolandsson, O., Hagg, E.. Janer, M., Rutledge. E., Gaur, L.K.. leh, B.T. see Chandrasekharappa, S.( Nilsson, M., Hallmans, G. & Lernmark, A. High GAD65 eh, IB .T. see¢ ‘hen, J.D autoantibody levels in nondiabetic adults are associated with eh, B.T. Multiple endocrine neoplasia, 588 HLA but not with CTLA-4 or INS VNTR, 447 helle, D.S. see Rosengren, A Romero-Ayala, L. see Marquez, M.F. rhompson, N.W. see Doherty, G.M rhomsen, T.F. see De Visser, C.1 Rose, P. see Cadet, E. Rosén, M. see Rosengren, A. rhorén, M. see Degerblad, M Rosengren, A., Thelle, D.S., Koster, M. & Rosén, M. Changing se horgeirsson, G. see Thrainsdottir, [.S ratio in acute coronary heart disease: data from Swedish hormaehlen, J. see Melchart, D 1ational registers 1984-99, 301 hrainsdottir, I.S., Hardarson, Th., Thorgeirsson, G., Sigvaldason, Rosenqvist, M. see Ryman, J H. & Sigfusson, N. Survival and trends of occurrence of left Rossing, P. see Jacobsen, P. ventricular hypertrophy, gender differences, 1967-92: Che Réssner, S. see Udden, J. Reykjavik Study, 418 2003 Blackwell Publishing Ltd Journal of Internal Medicine 253: 671-675 AUTHOR INDEX C7 Tietge, U.J.F., Genschel, J. & Schmidt, H.H.-J. A Q136Stop Vitols, S. Paracetamol hepatotoxicity at therapeutic doses, 95 mutation in the ARH gene causing autosomal recessive Vuotto, P. see Mossetti, G. hypercholesterolaemia with severely delayed LDL catabolism, 582 Wang, A.Y.-M. see Szeto, C.-C. Tobler, K. see Kurkciyan, I. Weatherby, S.J. see Ma, Y.T. Tonet, J. see Marquez, M.F. Webb, G. see Stanciu, I.N. Torgerson, J.S. see Lantz, H. Weidenhammer, W. see Melchart, D. lur-Kaspa, R. see Ben-Ari, Z. Westheim, A. see Os, I. Wieland, E. see Schettler, V Udden, J., Bjdrntorp, P., Arner, P., Barkeling, B., Meurling, L. & Wikstrand, J. see Schmidt, C. Rossner, S. Effects of glucocorticoids on leptin levels and Wikstr6m, B. see Messner, T. eating behaviour in women, 225 Nilliams, A.C. see Ma, Y.T. Ueshima for the NIPPON DATAS80O Research Group, H. see Winer, J.B. see Ma, Y.1 Okamura, T. Winslow, R.M. Current status of blood substitute research Usta, M., Ersoy, A., Dilek, K., Ozdemir, B., Yavuz, M., Giilliilii, M. towards a new paradigm, 508 & Yurtkuran, M. Efficacy of losartan in patients with primary Wollmer, P. see Engstrém, G. focal segmental glomerulosclerosis resistant to immunosup- Wong, T.Y.-H. see Szeto, C.-C. Wranne, B. see Lindenberger, M pressive treatment, 329 Valdes Socin, H. see Beckers, A. Yavuz, M. see Usta, M. Vanderschueren, S. see Knockaert, D.C. Yeh, L.-H. & Alayash, A.I. Redox side reactions of haemoglobin Veloso, H.H. & De Paola, A.A.V. Atrial fibrillation or flutter and and cell signalling mechanisms, 518 stroke: effectiveness of oral anticoagulation in clinical Yoshida, H. see Nakanishi, N. practice, 92 Yurtkuran, M. see Usta, M Verhave, J.C., Baljé-Volkers, C.P., Hillege, H.L., De Zeeuw, D. & De Jong, P.E. The reliability of different formulae to predict Zannoni, G. see Candelli, M. creatinine clearance, 563 Zhang, C. see Chen, J.D. Viceconti, R. see Mossetti, G. Ziegenhagen, M.W. & Miiller-Quernheim, J. The cytokine network Vilstrup, H. see Aagaard, N.K. in sarcoidosis and its clinical relevance, 18 © 2003 Blackwell Publishing Ltd Journal of Internal Medicine Journal of Internal Medicine 2003; 253: 676 Keyword index %)-antitrypsin deficiency, 351 coronary heart disease, homocysteine, 284, 293 43243G mitochondrial DNA (mtDNA) cost, 472 HRPT2, 634 mutation, 381 cost-elfectiveness, 4 human atrial natriuretic peptide, 439 acromegaly, 599 C-reactive protein, 153 human leucocyte antigen, 447 acupuncture, 181 CTL (cytotoxic T lymphocyte), 402 hydroxychloroquine, 41 acute myocardial infarction, 320, 666 Cushing's disease, 454 hypercholesterolaemia, 425 aetiology, 411 cyclooxygenase, 643 hyperparathyroidism, 634 age, 232 hypertension, 430, 472, 643 airway hyper-responsiveness, 35 2-D echocardiography, 41 1 hypertrophic, 490 alcohol intake, 367 diabetes, 217, 293, 472, 574 hypoxia-inducible factor, 518 all-trans retinoic acid, diabetes complications, 189 alveolitis, 18 diabetes mellitus, 189 IBD, 386 angina, 301 diabetic nephropathy, 3+ >> IGF-I, 454 angiogenesis, 8] diagnosis, 120 immunosuppression, 31 angiotensin receptor blockade, 329 diagnosis of restenosis, 253 infectious diseases, 402 anticoagulation, 76 diagnostic laparoscopy, 616 inflammation, 153 antioxidant, 527 diagnostic strategy, 263 insulin, 136 Arctic Oscillation index, 666 dialysis, 335 insulin receptor, 484 artificial red blood cells, 527 disease activity, 18 insulin resistance, 574 ASA, 472 DNA vaccines, 402 insulinoma, 484 atherosclerosis, 425 DOK1, 627 interleukin-6, 153 atrial fibrillation, 76 drug development, 46 intestinal pseudo-obstruction, 38 atrioventricular block, 386 islet cell tumour, 590 attributable risk, 169 elderly, 263 autoimmunity, 447 endocrine function, 454 Japanese men, 367 azathioprine, 41 endothelial damage, 8 | jaw tumour, 634 environment, 120 un D, 606 B-cell function, 232 epidemiology, 136, 276, 418 biochemical markers, 311] episodic fever, 263 K-ATPase, 359 birth weight, 343 excessive daytime sleepiness, 536 blood donation, 498 exercise, 8] amivudine, 544 blood substitutes, 498, 508, 518, 527 eft ventricular hypertrophy, 418 blood transfusion, 498 familial hyper-cholesterolaemia, 161 eptin, 225 body composition, 463 fasting, 375 LightCycler’, 201 body mass index, 563 FDG-PET, 263 ipids, 16] bronchoalveolar lavage, 18 fever of unknown origin, 22¢6 3 ipoprotein lipase deficiency, 208 focal segmental glomerulosclerosis, 329 iver cirrhosis, 359 cancer, 46, 402 folic acid, 293 liver transplantation, 544 cardiac surgery, 411 follow-up studies, 284 oop diuretics, 439 ‘ardiac tamponade, 41 1 food intake, 225 osartan, 329 ‘ardiac troponin T, 153 forced vital capacity, 574 ung function, 351 ‘ardiomyopathy, 490 free radical scavenging enzymes, 201 ‘ardiopulmonary resuscitation, 128 malnutrition, 240 -ardiovascular, 136 gamma knife surgery, 454 medullary thyroid carcinoma, 616 ‘ardiovascular disease, 161, 293 gastrinoma, 590 MELAS, 381 -ardiovascular risk factors, 463 gastroplasty, 375 MEN1, 590, 599, 606 cardioversion, 76 gender differences, 418 menin, 606 case-control, 653 gene polymorphisms, 439 message framing, 498 cathether ablation, 490 genes, 120, 402 metabolic control, 189 chest pain, 311 genetic testing, 217 methotrexate, 41 cholesterol, 169 GHRH-GH-IGF axis,¢ methylmalonic acid, 146 cholesteryl ester transfer, 208 glomerular filtration microencapsulation, 527 chronic alcoholism, 359 glucocorticoids, 225 migraine, 181 chronic fatigue and arthralgia, 217 glucose, 574 mitochondrial encephalomyopathy, 381 chronic renal disease, 153 glucose—insulin infusion, 1! MONICA, 320, 666 citrate handling, 194 glutamate decarboxylase, 447 mortality, 136, 169, 276, 320, 666 clinical efficacy, 402 multiple endocrine neoplasia, 616 clinical trials, 46 haemochromatosis, 217 multiple endocrine neoplasia type 1 Cockcroft-Gault, 563 haemodialysis, 201 (MEN1), 590, 599, 606 coffee, 653 haemoglobin, 508, 518 multiple endocrine neoplasia type 2, cohort, 169 HDL, 208 multiple endocrine neoplasia type | complication, 128 heart arrest, 128 syndrome, 599 congestive heart failure, 439 Hepatitis B, 544 muscle magnesium, 359 coronary, 169 hepatotoxicity, 240 muscle strength, 359 coronary artery disease, hereditary fever, 263 myocardial infarction, 128, 284, 301, coronary disease, 301 hirsutism, 484 425, 653 676 © 200{ 3 Blackwell Publishing Ltd KEYWORD INDEX Na, 359 pre-hospital phase, 311 smoking status, 367 nanoencapsulation, 527 prevalence, 660 SNT/FRS2, 627 neck dissection, 616 prevention, 293, 553 snus, 660 neck reoperation, 616 prognosis, 18, 284 spirometry, 574 nephrolithiasis, 194 protein interaction, 606 standardized mortality ratio, 276 Netherlands, 553 proteinuria, 329 stanniocalcin 1, 627 nonsteroidal anti-inflammatory drugs, stress testing, 253 643 sudden cardiac death, 320, 666 quality of life, 146 northern Sweden, 666 sumatriptan, 181] nuclear localization, 606 survival, 153 radiation treatment, 454 obesity, 136, 225, 463 randomized controlled trial, 181 -helper 1 immunity, 31 occult gastrointestinal bleeding, 490 reciprocal creatinine, 335 thrombolysis, 128 oedema, 643 relative polycythaemia, 481 time trends, 320 oestrone, 232 renal failure, 335, 643 I'NF-x, 18 osteoporosis, 439 resistance, 544 transfusion, 508 oxidized low density lipoproteins, 425 restenosis, 253 treatment, 31, 463 oxygen carriers, 527 RET isoforms, 627 treatment resistant, 329 oxygen radicals, 201 RET proto-oncogene, 616 tumour necrosis factor, 31 retinoids, 375 tumour suppressor, 606 ppaanrcarceeatsa,m ol5,9 0 240 rriestki noals, ses3s7m5e nt, 553 ttyyppee 11 ddiiaabbeetteess, me3l4l3i,t us4,4 7 343 risk communication, 498 Parafibromin, 634 percutaneous transluminal coronary rriisskk fpaecrtcoerp(ts)i,o ns,1 36,4 981 61, 284, 418, 553 ultrasonography, 430 angioplasty, 253 pericardial effusion, 411 vascular endothelial growth factor, 81 pericardiocentesis, 411] sarcoidosis, 18, 31, 41 vitamin A, 375 pericarditis, 386 screening, 169 vitamin B-12 deficiency, 146 phospholipid transfer, 208 serum creatinine, 563 vitamin D receptor, 439 physical activity, 276 serum iron measurements, 2 vitamin D receptor polymorphisms, 194 pituitary adenomas, 599 severe obesity, 536 VLCD, 463 pituitary gland, 454 sex, 447 von Willebrand factor, 81 plaque, 430 sFlt-1, 81 plasma cholesterol, 425 SHC, 627 warfarin sodium, 76 polycystic ovarian syndrome, 484 signalling pathways, 518 weight maintenance, 463 polycythaemia, 481 sleep quality, 536 weight/length ratio, 343 polygenic, 120 sleep-related symptoms, 536 white blood cell count, 367 population, 301 smokeless tobacco, 660 white blood cells, 201, 367 predialysis, 153 smoking, 232, 660 whole blood viscosity, 232 prednisone, 41 smoking cessation, 660 women, 225, 232>>, 301 2003 Blackwell Publishing Ltd Journal of Internal Medicine 253: